Show simple item record

Hemija prostanoida i antagonista CCK2 receptora

dc.creatorVladimirov, Sote
dc.creatorAgbaba, Danica
dc.date.accessioned2019-09-02T10:58:29Z
dc.date.available2019-09-02T10:58:29Z
dc.date.issued2004
dc.identifier.issn0004-1963
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/494
dc.description.abstractThe involvement of more neurotrasmiters, hormones and autocoids in the control of gastric acid secretion has resulted in a number of therapeutic approches directed toward achieving its inhibition. Although significant progress in obtaining CCK2 gastrin receptor antagonists as vell as EP3 receptor agonists has been made in recent years, compounds from either of these groups seem unlikely to dislodge the irreversibile proton-pump inhibitors and histamine H2-angonists as the preferred treatment in acid-related disoreders at present. All of the potencially antiulcerative useful prostanoids are in general synthetically produced closely related analogs of natural prostaglandins PGE1 and PGE2. For example, it was hoped that EP3 receptor agonists such as misoprostol and newly sinthetised, selectivelly and more active GR63799X, might prove beneficial as cytoprotective agents.en
dc.description.abstractUčešće brojnih endokrinih hormona i neurotransmitera u kontroli gastrične sekrecije pruža mogućnost različitih terapijskih pristupa u tretiranju ulkusne bolesti i stanja hipersekrecije. Inhibitori protonske pumpe, H2 antagonisti histamina i muskarinskih receptora su veoma efikasni i bezbedni antiulkusni i antihipersekretorni lekovi. Iz ove grupe lekova u kliničkoj fazi ispitivanja su novi, reverzibilni inhibitori protonske pumpe i antagonisti H2 receptora druge generacije. U kliničkoj fazi ispitivanja nalaze se i brojni antagonisti CCK2-receptora kao potencijalni inhibitori gastrične sekrecije. Pored inhibicije gastrične sekrecije ovi potencijalni lekovi imaju i antianksiozni efekat. Citoprotektivna zaštita prostanoida, agonsta EP3 receptora za per os primenu je noviji pristup naročito u hroničnoj terapiji nesteroidnim antireumaticima koji mogu biti uzročnici ozbiljnih neželjenih efektata kao što su hipersekrecija gastritis, ulkus i gastrične hemoragije.sr
dc.publisherSavez farmaceutskih udruženja Srbije, Beograd
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-sa/4.0/
dc.sourceArhiv za farmaciju
dc.subjectGastrinen
dc.subjectProstanoidsen
dc.subjectMisoprostolen
dc.subjectCCK2 antagonistsen
dc.subjectAntiulcerative drugsen
dc.subjectgastrinsr
dc.subjectprostanoidisr
dc.subjectmizoprostolsr
dc.subjectantagonisti CCK2sr
dc.subjectantiulkusni lekovisr
dc.titleThe chemistry of prostanoids and CCK2 antagonistsen
dc.titleHemija prostanoida i antagonista CCK2 receptorasr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractВладимиров, Соте; Aгбаба, Даница; Хемија простаноида и антагониста ЦЦК2 рецептора; Хемија простаноида и антагониста ЦЦК2 рецептора;
dc.citation.volume54
dc.citation.issue3
dc.citation.spage211
dc.citation.epage225
dc.citation.other54(3): 211-225
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/2016/492.pdf
dc.identifier.rcubconv_149
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record